F

Fluidigm Corp
F:FLB

Watchlist Manager
Fluidigm Corp
F:FLB
Watchlist
Price: 1.54 EUR 2.67% Market Closed
Market Cap: 570.4m EUR
Have any thoughts about
Fluidigm Corp?
Write Note

Fluidigm Corp
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Fluidigm Corp
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
F
Fluidigm Corp
F:FLB
Current Portion of Long-Term Debt
$54.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Current Portion of Long-Term Debt
$4.1B
CAGR 3-Years
501%
CAGR 5-Years
44%
CAGR 10-Years
3%
Danaher Corp
NYSE:DHR
Current Portion of Long-Term Debt
$1.2B
CAGR 3-Years
456%
CAGR 5-Years
2%
CAGR 10-Years
33%
Mettler-Toledo International Inc
NYSE:MTD
Current Portion of Long-Term Debt
$185.8m
CAGR 3-Years
51%
CAGR 5-Years
31%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Current Portion of Long-Term Debt
$1.2B
CAGR 3-Years
137%
CAGR 5-Years
66%
CAGR 10-Years
50%
No Stocks Found

Fluidigm Corp
Glance View

Market Cap
569.7m EUR
Industry
Life Sciences Tools & Services

Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.

FLB Intrinsic Value
1.08 EUR
Overvaluation 30%
Intrinsic Value
Price
F

See Also

What is Fluidigm Corp's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
54.8m USD

Based on the financial report for Jun 30, 2024, Fluidigm Corp's Current Portion of Long-Term Debt amounts to 54.8m USD.

What is Fluidigm Corp's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 1Y
1 091%

Over the last year, the Current Portion of Long-Term Debt growth was 1 091%.

Back to Top